(Q36773469)

16 August 2017

1 reference

title

Technology insight: cytotoxic drug immunoconjugates for cancer therapy (English)

1 reference

16 August 2017

0 references

Alejandro D Ricart

1

1 reference

PubMed ID

17392715

16 August 2017

Anthony W Tolcher

series ordinal

2

1 reference

16 August 2017

1 April 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

1 reference

16 August 2017

4

1 reference

16 August 2017

245-255

1 reference

16 August 2017

4

1 reference

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

16 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Arming antibodies: prospects and challenges for immunoconjugates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

The history of ricin, abrin and related toxins

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Immunotoxin therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

DNA bending is a determinant of calicheamicin target recognition

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Semisynthetic maytansine analogues for the targeted treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Perspectives on anti-HER monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Tumor-Specific Novel Taxoid−Monoclonal Antibody Conjugates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0774

7 January 2021

Identifiers

DOI

10.1038/NCPONC0774

1 reference

16 August 2017

1 reference

PubMed ID

17392715